![]() |
市场调查报告书
商品编码
1350965
冷冻干燥注射药物市场规模-按药物类型(抗感染剂、抗凝血剂、荷尔蒙)、适应症(自体免疫、呼吸、胃肠道、肿瘤)、包装类型、分销管道、交付类型、全球预测,2023 -2032年Lyophilized Injectable Drugs Market Size-By Drug type (Anti-infectives, Anticoagulants, Hormones), Indication (Autoimmune, Respiratory, Gastrointestinal, Oncology), Packaging Type, Distribution Channel, Delivery Type, Global Forecast, 2023-2032 |
2023年至2032年,全球冷冻干燥注射药物市场的复合年增长率将达到13.5%。製药业不断的研发努力导致越来越多的生物药物需要冷冻干燥以保持稳定性和更长的保质期。这些药物,包括疫苗和单株抗体,对于治疗各种疾病至关重要,从而提振了市场。
全球对个人化医疗的需求正在上升,因此需要生产可以轻鬆重建以用于个人化治疗方案的冷冻干燥药物。此外,不断扩大的肿瘤学领域严重依赖用于化疗和标靶治疗的冷冻干燥药物,加剧了市场成长。
随着製药和生技产业研发活动的持续推进,冷冻干燥注射药物市场前景将在 2023-2032 年增强。例如,2023 年 8 月,专业生命科学公司 Revive Therapeutics 开始研究布西拉明的新配方。 Revive 发起了与滑铁卢大学的赞助研究合作,开发一种创新的冻干布西拉明注射製剂。这项研究的重点是满足突发公共卫生事件的需要。
整个冷冻干燥注射药物产业根据药物类型、适应症、包装类型、分销管道和地区进行分类。
以药物类型来看,2023年至2032年抗肿瘤领域的复合年增长率将达到13.3%。用于癌症治疗的抗肿瘤药物通常需要冷冻干燥以维持其稳定性和功效。这个过程使这些药物能够保存更长时间而不失去效力。由于癌症仍然是全球健康挑战,随着肿瘤治疗的进步,抗肿瘤领域的冷冻干燥注射药物市场需求持续成长。
就包装类型而言,从 2023 年到 2032 年,预填充器械市场将显着增加。这些器械提供了药物输送的便利性和准确性,使其对冷冻干燥注射药物特别有吸引力。预充式註射器和其他输送系统可确保精确剂量并降低污染风险,进而提高病患的安全性和依从性。此外,医疗保健专业人员也欣赏其易于管理的特点。
根据预测,从2023 年到2032 年,呼吸系统疾病领域的复合年增长率将达到12%。许多呼吸系统疾病的治疗方法,包括严重气喘和慢性阻塞性肺病(COPD),都是透过冷冻干燥注射剂提供的。冷冻干燥可确保这些药物的稳定性和保存期限,同时保留其效力。随着全球呼吸系统疾病盛行率的上升,冷冻干燥注射药物市场在该治疗领域的整体份额正在成长。
从分销管道来看,医院药房细分市场从 2023 年到 2032 年将呈现高增长率。这些药物具有延长保质期、稳定性和易于重构等优势,对于及时、高效的患者护理至关重要。医院药局依赖冻干药物进行各种关键应用,从紧急治疗到专业治疗。因此,医院药局对冷冻干燥注射剂市场收入的贡献很大。
从地区来看,欧洲冷冻干燥注射药物产业从2023 年到2032 年将呈现出值得称讚的复合年增长率。欧洲医疗保健系统强调病患照护的安全性、品质和精确性,而冷冻干燥药物与这些优先事项完美契合。这些药物确保稳定性、更长的保质期和易于管理,并满足该地区严格的监管标准。随着人口老化和医疗保健需求不断增长,欧洲对这些药物的需求持续增长。
Global Lyophilized Injectable Drugs Market will witness a 13.5% CAGR between 2023 and 2032. The continuous R&D efforts by the pharmaceutical industry are leading to an increasing number of biological drugs that require lyophilization for stability and longer shelf life. These drugs, including vaccines and monoclonal antibodies, are vital in treating various diseases, thereby boosting the market.
The global demand for personalized medicine is rising, necessitating the production of lyophilized drugs that can be easily reconstituted for individualized treatment regimens. Furthermore, the ever-expanding field of oncology relies heavily on lyophilized drugs for chemotherapy and targeted therapies, intensifying market growth.
As the pharmaceutical and biotechnology sectors continue to advance in research and development activities, the lyophilized injectable drugs market outlook will strengthen over 2023-2032. For instance, in August 2023, Revive Therapeutics, a specialized life sciences company, commenced work on a fresh formulation of Bucillamine. Revive initiated a sponsored research collaboration with the University of Waterloo to develop an innovative lyophilized Bucillamine injectable formulation. This research focuses on meeting the needs of public health emergencies.
The overall Lyophilized Injectable Drugs industry is classified based on drug type, indication, packaging type, distribution channel, and region.
By drug type, the anti-neoplastics segment will witness a 13.3% CAGR from 2023 to 2032. Anti-neoplastic drugs used in cancer treatment often require lyophilization to maintain their stability and efficacy. This process enables these drugs to be stored for longer periods without losing potency. As cancer remains a global health challenge, and with advancements in oncology therapies, the lyophilized injectable drugs market demand in the anti-neoplastics segment continues to grow.
Regarding the packaging type, the prefilled devices segment will augment significantly from 2023 to 2032. These devices offer convenience and accuracy in drug delivery, making them particularly appealing for lyophilized injectable drugs. Prefilled syringes and other delivery systems ensure precise dosing and reduce the risk of contamination, enhancing patient safety and compliance. Additionally, healthcare professionals appreciate the ease of administration.
By indication, the respiratory diseases segment will register a 12% CAGR from 2023 to 2032. Many therapies for respiratory ailments, including severe asthma and chronic obstructive pulmonary disease (COPD), are delivered through lyophilized injectables. Lyophilization ensures the stability and shelf life of these drugs while preserving their potency. With the global prevalence of respiratory diseases on the rise, the overall share of the lyophilized injectable drugs market in this therapeutic area is growing.
By distribution channel, the hospital pharmacies segment will exhibit a high growth rate from 2023 to 2032. These medications offer advantages such as extended shelf life, stability, and ease of reconstitution, making them essential for timely and efficient patient care. Hospital pharmacies rely on lyophilized drugs for various critical applications, from emergency treatments to specialized therapies. Thus, hospital pharmacies contribute greatly to the lyophilized injectable drugs market revenue.
Regionally, Europe lyophilized injectable drugs industry will showcase a commendable CAGR from 2023 to 2032. European healthcare systems emphasize safety, quality, and precision in patient care, and lyophilized drugs align perfectly with these priorities. These drugs ensure stability, longer shelf life, and ease of administration, meeting the stringent regulatory standards in the region. With an aging population and growing healthcare needs, the demand for these drugs in Europe continues to grow.